This analysis identifies early mortality risks in metastatic colorectal cancer patients, supporting treatment decisions regarding chemotherapy or supportive care.
Our predictive model may help identify patients at high risk of early mortality after regorafenib or trifluridine/tipiracil initiation and support shared decision-making between clinicians and patients regarding further chemotherapy or best supportive care.
No takes yet. Share an insight, caveat, or question.
Masuishi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: